First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall; M Boyer; V Ganju; B Hughes; N Pavlakis; B Solomon; S Varma; T Berghmans; J-L Canon; I Demedts; A Janssens; R Louis; T Pieters; D Schallier; V Surmont; C Maciel da Silva; C-G Moreira Ferreira; V Hirsh; A Joy; F Laberge; W Morzycki; R Wierzbicki; B Han; X Liu; S Qin; Y Shi; Y Wang; G Wu; Y-L Wu; C Zhou; J Ahvonen; F Barlesi; J Cadranel; E Dansin; J Fayette; J-F Morere; D Moro-Sibilot; J-L Pujol; E Quoix; G Zalcman; N Frickhofen; C-P Schneider; T Wehler; T Mok; P So; S Cuffe; A Bearz; C Boni; F Cappuzzo; F Cognetti; F De Braud; T De Pas; D Galetta; M Migliorino; D Rocco; G Scagliotti; P Tagliaferri; M Tiseo; K Aoe; T Hida; T Kato; T Kozuki; K Nakagawa; S Niho; M Nishio; H Nokihara; M Satouchi; T Seto; T Takahashi; J-S Ahn; D-W Kim; S-W Kim; G Berchem; O Arrieta Rodriguez; B Biesma; A-M Dingemans; E Smit; A Helland; F Barata; V Gorbunova; G Manikhas; S Orlov; S Leong; H-L Lim; R Soo; E-H Tan; A Nosworthy; M Codes Villena; E Felip; P Garrido Lopez; D Isla Casado; N Martinez Banaclocha; S Ponce Aix; N Reguart Aransay; D Rodriguez Abreu; J Trigo Perez; O Gautschi; M Pless; A Zippelius; G-C Chang; Y-H Tsai; Y Shparyk; F Blackhall; N Steele; V Armenio; K Dragnev; M Dugan; S Gadgeel; D Gerber; S Graziano; S Gurubhagavatula; L Horn; S Jalal; R Lauer; R Mehra; T Mekhail; H Mirshahidi; S Pakkala; J Polikoff; H Raftopoulos; M Saleh; R Salgia; S Waqar

Journal article

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D Wilner, Jennifer Tursi, Fiona Blackhall, M Boyer, V Ganju, B Hughes, N Pavlakis, B Solomon Show all

NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2014

DOI: 10.1056/NEJMoa1408440

Abstract

BACKGROUND: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS: We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of body-surface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 t..

View full abstract